Drug Trial Radar · NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,410
Planned (sponsor's estimate)
Start
Jan 6, 2026
Primary completion
Feb 27, 2029
Study completion Aug 26, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC. * Is not a candidate for complete surgical resection or curative chemoradiotherapy. * Do not have known actionable genomic alterations * Be treatment naïve for advanced or metastatic disease Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion: * Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor. * Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor. Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects. The study will include regular visits for: * Treatment and health checks: while participant continues receiving treatment. * Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.
Conditions
- Advanced Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Metastatic Non Small Cell Lung Cancer
- Lung Cancer
Interventions
PF-08634404Biological
Solution for infusion
PembrolizumabBiological
Injection for IV use
Chemotherapy Regimen 1Drug
Injection for IV use
Chemotherapy Regimen 2Drug
Injection for IV use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Approximately 39 months
- Progression Free Survival (PFS) assessed by blinded independent central review (BICR)Time frame: Approximately 32 months
Locations
484 sites in 20 countries. Site status is shown where the registry gives one.
Pioneer Research Center
Bullhead City, Arizona · Recruiting
Ironwood Cancer & Research Centers
Chandler, Arizona · Recruiting
Ironwood Cancer & Research Centers
Gilbert, Arizona · Recruiting
Ironwood Cancer & Research Centers
Glendale, Arizona · Recruiting
Ironwood Cancer & Research Centers
Goodyear, Arizona · Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona · Recruiting
Ironwood Cancer & Research Centers
Mesa, Arizona · Recruiting
Ironwood Cancer & Research Centers
Phoenix, Arizona · Recruiting
Ironwood Cancer & Research Centers
Scottsdale, Arizona · Recruiting
Highlands Oncology Group
Fayetteville, Arkansas · Recruiting
Highlands Oncology Group
Rogers, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Oncura Health - Anaheim
Anaheim, California · Recruiting
Memorial Care Orange Coast Medical Center Attn
Fountain Valley, California · Recruiting
MemorialCare Orange Coast Medical Center
Fountain Valley, California · Recruiting
OC Blood and Cancer Care
Fountain Valley, California · Recruiting
Oncura Health - Fountain Valley
Fountain Valley, California · Recruiting
Oncura Health - Corporate (Central IDS & Regulatory Only)
Glendale, California · Recruiting
Memorial Care Saddleback Medical Center Attn
Laguna Hills, California · Recruiting
MemorialCare Saddleback Medical Center
Laguna Hills, California · Recruiting
Stockton Hematology Oncology Medical Group
Lodi, California · Recruiting
Memorial Care Long Beach Medical Center
Long Beach, California · Recruiting
Cancer and Blood Research Center, LLC (Storage)
Los Alamitos, California · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
Oncura Health - Good Samaritan
Los Angeles, California · Recruiting
California Research Institute
Los Angeles, California · Recruiting
Stockton Hematology Oncology Medical Group
Manteca, California · Recruiting
Stockton Hematology Oncology Medical Group
Modesto, California · Recruiting
Oncura Health - Riverside
Riverside, California · Recruiting
Roseville Medical Plaza Care Center
Roseville, California · Not yet recruiting
Sutter Medical Center, Sacramento Infusion Center at Roseville
Roseville, California · Not yet recruiting
Sutter Roseville Medical Center
Roseville, California · Not yet recruiting
Sansum Clinic
Santa Barbara, California · Recruiting
Sansum Clinic
Solvang, California · Recruiting
Stockton Hematology Oncology Group
Stockton, California · Recruiting
Cancer and Blood Specialty Clinic
Torrance, California · Recruiting
Stockton Hematology Oncology Medical Group
Tracy, California · Recruiting
Oncura Health - Valley Presbyterian
Van Nuys, California · Recruiting
Florida Cancer Specialists
Bonita Springs, Florida · Recruiting
Florida Cancer Specialists
Bradenton, Florida · Recruiting
Showing 40 of 484 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.